U.S. Medicines Marketed by Our Partners

All therapeutic information provided is intended for the U.S. audience only.

These treatments may not be available in countries outside the U.S. or may be available under a different trademark; in different strengths; or for different indications. Countries outside the U.S. may have different regulatory requirements that would call for different information to be available.


U.S. Medicines Licensed to Our Partners

We have granted licenses to medicines which enable third parties to develop, make available and, in some cases, manufacture for which we receive royalties and/or manufacturing revenues.

Such arrangements in the U.S. include the following:

Product Logo

Indication: Opioid-induced constipation in adult patients with chronic, non-cancer pain

Discovered by Nektar

Partner
Partner In partnership with Partner

About Nektar and AstraZeneca Agreement for Movantik

Under our global agreement with AstraZeneca, AstraZeneca is responsible for all development and commercialization. We receive escalating royalties on net U.S. sales of Movantik starting at 20 percent. We are also eligible to receive additional tiered sales milestone payments based upon global net revenue of Movantik.

MOVANTIK is a trademark of the AstraZeneca group of companies. AstraZeneca and their partner, Daiichi Sankyo, provide Movantik in the U.S.


Product Logo

Indication: Hemophilia A

Discovered by Nektar

Partner
Partner

Nektar Therapeutics and Baxalta (a division of Shire plc) Agreement for ADYNOVATE

Under our collaboration with Baxalta, a wholly-owned subsidiary of Shire plc (formerly Baxter), we developed ADYNOVATE, an extended half-life recombinant factor VIII (rFVIII) treatment for Hemophilia A based on ADVATE® [Antihemophilic Factor (Recombinant)]. Baxalta is responsible for development and commercialization and we supply manufacturing materials for a portion of the supply chain to manufacture ADYNOVATE.

We receive escalating royalties of between 4-6 percent on global net revenue of ADYNOVATE up to $1.2 billion in revenue; for revenue above $1.2 billion, we receive a flat 13 percent royalty. Nektar Therapeutics is also eligible to receive additional tiered revenue milestone payments based upon global net revenue of ADYNOVATE.


U.S. Medicines Using Our Technologies

We have granted licenses to our technologies which enable third parties to develop, provide and, in some cases, manufacture for which we receive royalties and/or manufacturing revenues.

ADYNOVATE and Baxalta are registered trademarks of Shire plc, its subsidiaries or affiliates.